APVO News and Press, Aptevo Therapeutics Inc.

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X (SOXS) fell 9.6% to $4.07 on volume of 673,374,347 shares ProShares Bitcoin ETF (BITO) rose 1.5% to $8.57 on volume of 326,768,067 shares Edible Garden AG Incorporated (EDBL) rose 0.0% to $0.116 on v...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X (SOXS) fell 16.1% to $3.775 on volume of 170,502,101 shares Edible Garden AG Incorporated (EDBL) fell 13.2% to $0.1007 on volume of 156,546,206 shares Rocket One Inc. (RKTO) rose 29.6% to $1.0399 on ...

SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced it has been awar...

By Meg Flippin, Benzinga DETROIT, MICHIGAN - June 9, 2026 ( NEWMEDIAWIRE ) - When it comes to treating metastatic cancers, the current approach is to destroy everything in the path to the tumor. But the collateral damage from that can be deadly.  A novel approach is to target the canc...

Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel imm...

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-s...

2026-05-13 09:35:06 ET More on Aptevo Therapeutics Seeking Alpha’s Quant Rating on Aptevo Therapeutics Historical earnings data for Aptevo Therapeutics Financial information for Aptevo Therapeutics Read the full article on Seeking Alpha For fur...

Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients Executive leadership transition complete. Jeff Lamothe appointed CEO; Marvin White assumes Executive Chair $60 million equity line of credit enhances fina...

Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO) today reported new clinical results fr...

By Meg Flippin, Benzinga DETROIT, MICHIGAN - March 27, 2026 ( NEWMEDIAWIRE ) - Acute myeloid leukemia (AML) is one of the most difficult blood cancers to treat – especially for older patients or those with other health conditions who cannot tolerate intensive chemotherapy. For many of th...